U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07821411) titled 'A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan' on Sept. 09.
Brief Summary: This study aims to evaluate the real-world persistence and adherence to ofatumumab (OMB) treatment in adult patients with relapsing multiple sclerosis (RMS). This is a non-interventional study using administrative claims data available in Germany and Japan.
Study Start Date: July 31
Study Type: OBSERVATIONAL
Condition:
Multiple Sclerosis
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Novartis Pharmaceuticals
Disclaimer: Curated by HT Syndication....